Amicus Therapeutics (FOLD) Misses Q2 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Amicus Therapeutics Announces Second Quarter 2023 Financial Results and Corporate Updates
August 8, 2023 7:00 AM EDT1H 2023 Revenue Growth of 16% at CER to $180.8M
Raising FY 2023 Galafold® Revenue Growth Guidance to 14%-18% at CER
EU Launch of Pombiliti® + Opfolda® Underway; U.S. and U.K. Approvals Expected 3Q 2023
Reducing 2023 Non-GAAP Operating Expense Guidance to $330M-$350M
Non-GAAP Profitability Projected in 2H 2023
Conference Call... More
